vs

Side-by-side financial comparison of CREATIVE REALITIES, INC. (CREX) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.

CREATIVE REALITIES, INC. is the larger business by last-quarter revenue ($23.9M vs $19.1M, roughly 1.2× NewAmsterdam Pharma Co N.V.). CREATIVE REALITIES, INC. runs the higher net margin — -8.2% vs -90.7%, a 82.5% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 117.2%). CREATIVE REALITIES, INC. produced more free cash flow last quarter ($-4.6M vs $-37.8M).

Creative Realities, Inc. is a provider of end-to-end immersive digital experience solutions, including interactive digital signage, content management software, and custom experiential design services. It primarily caters to retail, hospitality, healthcare, corporate workplace, and public sector clients across North America, helping brands enhance customer engagement and operational efficiency.

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

CREX vs NAMS — Head-to-Head

Bigger by revenue
CREX
CREX
1.2× larger
CREX
$23.9M
$19.1M
NAMS
Growing faster (revenue YoY)
NAMS
NAMS
+622.8% gap
NAMS
740.1%
117.2%
CREX
Higher net margin
CREX
CREX
82.5% more per $
CREX
-8.2%
-90.7%
NAMS
More free cash flow
CREX
CREX
$33.2M more FCF
CREX
$-4.6M
$-37.8M
NAMS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
CREX
CREX
NAMS
NAMS
Revenue
$23.9M
$19.1M
Net Profit
$-2.0M
$-17.4M
Gross Margin
47.9%
Operating Margin
1.9%
-186.1%
Net Margin
-8.2%
-90.7%
Revenue YoY
117.2%
740.1%
Net Profit YoY
30.8%
55.5%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CREX
CREX
NAMS
NAMS
Q4 25
$23.9M
Q3 25
$10.5M
Q2 25
$13.0M
$19.1M
Q1 25
$9.7M
Q4 24
$11.0M
$12.8M
Q3 24
$14.4M
$29.1M
Q2 24
$13.1M
Q1 24
$12.3M
Net Profit
CREX
CREX
NAMS
NAMS
Q4 25
$-2.0M
Q3 25
$-7.9M
Q2 25
$-1.8M
$-17.4M
Q1 25
$3.4M
Q4 24
$-2.8M
$-92.2M
Q3 24
$54.0K
$-16.6M
Q2 24
$-615.0K
Q1 24
$-109.0K
Gross Margin
CREX
CREX
NAMS
NAMS
Q4 25
47.9%
Q3 25
45.3%
Q2 25
38.5%
Q1 25
45.7%
Q4 24
44.2%
Q3 24
45.6%
Q2 24
51.8%
Q1 24
46.9%
Operating Margin
CREX
CREX
NAMS
NAMS
Q4 25
1.9%
Q3 25
-68.9%
Q2 25
-10.2%
-186.1%
Q1 25
-7.4%
Q4 24
-6.5%
-338.5%
Q3 24
7.9%
-85.9%
Q2 24
4.5%
Q1 24
-0.6%
Net Margin
CREX
CREX
NAMS
NAMS
Q4 25
-8.2%
Q3 25
-74.5%
Q2 25
-13.9%
-90.7%
Q1 25
34.6%
Q4 24
-25.8%
-721.7%
Q3 24
0.4%
-57.2%
Q2 24
-4.7%
Q1 24
-0.9%
EPS (diluted)
CREX
CREX
NAMS
NAMS
Q4 25
Q3 25
$-0.75
Q2 25
$-0.17
$-0.15
Q1 25
$0.32
Q4 24
$-0.28
$-0.91
Q3 24
$0.01
$-0.18
Q2 24
$-0.06
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CREX
CREX
NAMS
NAMS
Cash + ST InvestmentsLiquidity on hand
$1.6M
$739.2M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$21.5M
$778.5M
Total Assets
$151.0M
$815.1M
Debt / EquityLower = less leverage
2.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CREX
CREX
NAMS
NAMS
Q4 25
$1.6M
Q3 25
$314.0K
Q2 25
$569.0K
$739.2M
Q1 25
$1.1M
Q4 24
$1.0M
$834.2M
Q3 24
$868.0K
$422.7M
Q2 24
$4.1M
Q1 24
$2.9M
Total Debt
CREX
CREX
NAMS
NAMS
Q4 25
$44.0M
Q3 25
$22.0M
Q2 25
$19.9M
Q1 25
$23.0M
Q4 24
$13.0M
Q3 24
$10.7M
Q2 24
$13.6M
Q1 24
$12.8M
Stockholders' Equity
CREX
CREX
NAMS
NAMS
Q4 25
$21.5M
Q3 25
$21.9M
Q2 25
$29.4M
$778.5M
Q1 25
$29.9M
Q4 24
$25.5M
$757.5M
Q3 24
$28.3M
$378.9M
Q2 24
$28.2M
Q1 24
$28.8M
Total Assets
CREX
CREX
NAMS
NAMS
Q4 25
$151.0M
Q3 25
$61.3M
Q2 25
$63.7M
$815.1M
Q1 25
$67.0M
Q4 24
$65.2M
$864.6M
Q3 24
$67.6M
$439.2M
Q2 24
$69.6M
Q1 24
$68.2M
Debt / Equity
CREX
CREX
NAMS
NAMS
Q4 25
2.04×
Q3 25
1.00×
Q2 25
0.68×
Q1 25
0.77×
Q4 24
0.51×
Q3 24
0.38×
Q2 24
0.48×
Q1 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CREX
CREX
NAMS
NAMS
Operating Cash FlowLast quarter
$-4.5M
$-37.7M
Free Cash FlowOCF − Capex
$-4.6M
$-37.8M
FCF MarginFCF / Revenue
-19.1%
-197.2%
Capex IntensityCapex / Revenue
0.4%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M
$-119.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CREX
CREX
NAMS
NAMS
Q4 25
$-4.5M
Q3 25
$-1.6M
Q2 25
$773.0K
$-37.7M
Q1 25
$-2.4M
Q4 24
$-1.4M
$-37.5M
Q3 24
$544.0K
$-12.5M
Q2 24
$2.3M
Q1 24
$1.9M
Free Cash Flow
CREX
CREX
NAMS
NAMS
Q4 25
$-4.6M
Q3 25
$-1.7M
Q2 25
$672.0K
$-37.8M
Q1 25
$-2.5M
Q4 24
$-1.4M
$-37.5M
Q3 24
$543.0K
$-12.6M
Q2 24
$2.3M
Q1 24
$1.9M
FCF Margin
CREX
CREX
NAMS
NAMS
Q4 25
-19.1%
Q3 25
-16.2%
Q2 25
5.2%
-197.2%
Q1 25
-25.2%
Q4 24
-12.5%
-293.5%
Q3 24
3.8%
-43.2%
Q2 24
17.3%
Q1 24
15.7%
Capex Intensity
CREX
CREX
NAMS
NAMS
Q4 25
0.4%
Q3 25
1.0%
Q2 25
0.8%
0.5%
Q1 25
0.1%
Q4 24
0.0%
0.0%
Q3 24
0.0%
0.3%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CREX
CREX
NAMS
NAMS
Q4 25
Q3 25
Q2 25
Q1 25
-0.73×
Q4 24
Q3 24
10.07×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CREX
CREX

Service And Other$17.3M72%
Managed Services$4.7M20%
Installation Services$1.7M7%

NAMS
NAMS

Segment breakdown not available.

Related Comparisons